Literature DB >> 18320527

Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.

H Ahmadieh1, R Taei, M Soheilian, M Riazi-Esfahani, H Ahadi.   

Abstract

PURPOSE: To evaluate the efficacy of combined single-session photodynamic therapy (PDT) and intravitreal bevacizumab (IVB) for treatment of neovascular age-related macular degeneration (AMD).
METHODS: In a prospective interventional case series, patients with subfoveal choroidal neovascularization (CNV) underwent PDT followed by 1.25 mg IVB injection. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) measurements were repeated at 6-week intervals and fluorescein angiography was performed after 12 weeks and when considered necessary thereafter. Repeat injections of IVB were performed based on fluorescein angiographic evidence of CNV leakage.
RESULTS: Fourteen eyes were included in this study. Mean follow-up was 52.4+/-15.2 weeks (range: 26-74 weeks). Initially, mean BCVA was 0.80+/-0.42 logMAR and mean central macular thickness (CMT) was 308+/88 microm. At week 12, BCVA improved to 0.62+/-0.47 logMAR (p=0.006) and CMT reduced to 186+/-53 microm (p=0.003). Corresponding results were 0.53+/-0.52 logMAR (p=0.02) and 193+/-78 microm (p=0.002) after 24 weeks. A second IVB injection was performed in 13 eyes with a mean interval of 16.3+/-5.9 weeks.
CONCLUSIONS: Combination therapy with single-session PDT and IVB can improve vision and reduce CMT in neovascular AMD. Repeat IVB injections may maintain the visual gain from the initial combination therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18320527     DOI: 10.1177/112067210801800222

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  8 in total

1.  Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.

Authors:  Ayse Oner; Koray Gumus; Hatice Arda; Yudum Yuce; Sarper Karakucuk; Ertugrul Mirza
Journal:  Doc Ophthalmol       Date:  2009-02-19       Impact factor: 2.379

2.  Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.

Authors:  Sandro Saviano; Pia Easter Leon; Alessandro Mangogna; Daniele Tognetto
Journal:  Digit J Ophthalmol       Date:  2016-06-30

3.  Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yusaku Yoshida; Takeya Kohno; Manabu Yamamoto; Tasuku Yoneda; Hisashi Iwami; Kunihiko Shiraki
Journal:  Jpn J Ophthalmol       Date:  2013-02-15       Impact factor: 2.447

4.  Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.

Authors:  Shigeru Honda; Yasuo Kurimoto; Yasuaki Kagotani; Hiroyuki Yamamoto; Hitoshi Takagi; Mamoru Uenishi
Journal:  Jpn J Ophthalmol       Date:  2009-12-18       Impact factor: 2.447

5.  Photodynamic therapy of choroidal neovascularization with enlargement of the spot size to include the feeding complex.

Authors:  Ilias Georgalas; Alexandros A Rouvas; Dimitrios A Karagiannis; Athanasios I Kotsolis; Ioannis D Ladas
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks.

Authors:  Alfredo Pece; Gaetano Russo; Federico Ricci; Vincenzo Isola; Ugo Introini; Giuseppe Querques
Journal:  Clin Ophthalmol       Date:  2010-06-24

7.  Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial.

Authors:  Niloofar Piri; Hamid Ahmadieh; Ramin Taei; Masoud Soheilian; Reza Karkhaneh; Alireza Lashay; Faegheh Golbafian; Mehdi Yaseri; Mohammad Riazi-Esfahani
Journal:  J Ophthalmic Vis Res       Date:  2014 Oct-Dec

8.  Angioid streaks, clinical course, complications, and current therapeutic management.

Authors:  Ilias Georgalas; Dimitris Papaconstantinou; Chrysanthi Koutsandrea; George Kalantzis; Dimitris Karagiannis; Gerasimos Georgopoulos; Ioannis Ladas
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.